Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Armand

Showing results (241-250 of 273) with videos related to

Pageof 28
Sort By:
The Oncologist|July 29, 2020
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent TherapyNicole A Carreau, Orrin Pail, Philippe Armand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2018
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin LymphomaMargaretha G M Roemer, Robert A Redd, Fathima Zumla Cader, et al.
Blood Advances|November 18, 2022
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantationReid W Merryman, Robert A Redd, Eleanor Taranto, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 14, 2019
Management of Immunotherapy-Related Toxicities, Version 1.2019John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Blood Advances|January 10, 2020
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantationMatthew J Frigault, Philippe Armand, Robert A Redd, et al.
Blood Advances|March 19, 2026
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapyRan Xu, Gongwei Wu, Siobhan Rice, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2020
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Blood|January 12, 2017
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphomaReid W Merryman, Haesook T Kim, Pier Luigi Zinzani, et al.
The Journal of Clinical Investigation|August 6, 2013
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cellsUte E Burkhardt, Ursula Hainz, Kristen Stevenson, et al.
The Oncologist|April 11, 2020
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin LymphomaReid W Merryman, Nicole A Carreau, Ranjana H Advani, et al.
Pageof 28

Showing results (241-250 of 273) with videos related to

Sort By:
Pageof 28
The Oncologist|July 29, 2020
Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent TherapyNicole A Carreau, Orrin Pail, Philippe Armand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2018
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin LymphomaMargaretha G M Roemer, Robert A Redd, Fathima Zumla Cader, et al.
Blood Advances|November 18, 2022
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantationReid W Merryman, Robert A Redd, Eleanor Taranto, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 14, 2019
Management of Immunotherapy-Related Toxicities, Version 1.2019John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Blood Advances|January 10, 2020
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantationMatthew J Frigault, Philippe Armand, Robert A Redd, et al.
Blood Advances|March 19, 2026
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapyRan Xu, Gongwei Wu, Siobhan Rice, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2020
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020John A Thompson, Bryan J Schneider, Julie Brahmer, et al.
Blood|January 12, 2017
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphomaReid W Merryman, Haesook T Kim, Pier Luigi Zinzani, et al.
The Journal of Clinical Investigation|August 6, 2013
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cellsUte E Burkhardt, Ursula Hainz, Kristen Stevenson, et al.
The Oncologist|April 11, 2020
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin LymphomaReid W Merryman, Nicole A Carreau, Ranjana H Advani, et al.
Pageof 28